Pharmaceuticals, Biotechnology and Life Sciences
LONDON–(BUSINESS WIRE)–#GlobalHealthcareLogisticsMarket–Technavio has been monitoring the healthcare logistics market and it is poised to grow by USD 33.64 bn during…
PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small…
NATESTO® now covered as a Preferred Brand by leading national pharmacy benefits manager TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF), a…
Findings from open-label switch period of Early AMPLE study show that high efficacy responses observed at week 24 with Orencia…
DUBLIN–(BUSINESS WIRE)–The “Global Artificial Intelligence (AI) in Drug Discovery Market 2020-2026 by Offering, Technology, Drug Type, Therapeutic Area, Application, End…
VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that…
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–#antibody—Distributed Bio, a global leader in computational optimization of fully human monoclonal antibody libraries, is pleased…
AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), said Wednesday that detailed preclinical results with its monoclonal antibody mAB C6-17 to treat Huntington’s Disease (HD) were published in the peer-reviewed journal Neurobiology of Disease.
–New management role underscores Company’s commitment to establishing and advancing its proprietary pipeline of GPCR modulating drug candidates– GHENT, Belgium–(BUSINESS…
–New management role underscores Company’s commitment to establishing and advancing its proprietary pipeline of GPCR modulating drug candidates– GHENT, Belgium–(BUSINESS…